Levofloxacin for BK virus prophylaxis following kidney transplantation a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 20, 2014, Pages 2106-2114

  Knoll, Greg A ^a,b   Humar, Atul ^c   Fergusson, Dean ^b   Johnston, Olwyn ^d   House, Andrew A ^e   Joseph Kim, S ^c   Ramsay, Tim ^b   Chassé, Michaël ^b   Pang, Xiaoli ^f   Zaltzman, Jeff ^g   Cockfield, Sandra ^h   Cantarovich, Marcelo ⁱ   Karpinski, Martin ^j   Lebel, Louise ^b   Gill, John S ^k,l,m  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j UNIVERSITY OF MANITOBA   (Canada)

^k ST PAUL S HOSPITAL   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK VIRUS INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HYPOGLYCEMIA; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; TENDINITIS; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE; ANTIBIOTIC PROPHYLAXIS; BK VIRUS; CLINICAL TRIAL; GENETICS; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; PROSPECTIVE STUDY; TUMOR VIRUS INFECTIONS; URINE; VIREMIA; VIROLOGY;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BK VIRUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LEVOFLOXACIN; MALE; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; TUMOR VIRUS INFECTIONS; URINE; VIRAL LOAD; VIREMIA;

EID: 84914147663     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.14721     Document Type: Article

References (33)

1. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093-2109.
2. US Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
3. American Society of Transplantation Infectious Disease Community of Practice. BK virus. Am J Transplant. 2004;4(suppl 10):89-91.
4. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J AmSoc Nephrol. 2007;2(suppl 1):S36-S46.
5. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79(10): 1277-1286.
6. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation.AmJ Transplant. 2013;13(suppl 4):179-188.
7. Alméras C, Foulongne V, Garrigue V, et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? a prospective study. Transplantation. 2008;85(8):1099-1104.
8. Ryan J, Zanabli A, Cosio F, Stegall M, Larson T, Griffin M. Outcomes of immunosuppression reduction in BK viremic kidney transplant recipients screened at 4 months post-transplant. Am J Transplant. 2007;7(suppl 2):537.
9. De Paolis P, Gervasio E, Tedesco M, et al. Impact of preemptive reduction of immunosuppression with serial monitoring for BK virus replication in renal transplant recipients undergoing short-term evaluation. Transplant Proc. 2009;41(4):1207-1209.
10. Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant. 2006;10(8):920-922.
11. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10(2):407-415.
12. Kotton CN, Kumar D, Caliendo AM, et al; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333-360.
13. American Society of Transplantation Infectious Disease Community of Practice. Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant. 2004;4(suppl 10):135-141.
14. Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J AmSoc Nephrol. 2010;5(7):1298-1304.
15. Wojciechowski D, Chanda R, Chandran S, et al. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012;94(11):1117-1123.
16. Humar A, Gill J, Johnston O, et al. Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial. Trials. 2013;14:185.
17. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. 1976;16:399-403.
18. Repchinsky C. Compendium of Pharmaceuticals and Specialties. Ottawa, ON: Canadian Pharmacists Association; 2007.
19. Paya C, Humar A, Dominguez E, et al; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611-620.
20. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009; 9(suppl 4):S78-S86.
21. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009;9(suppl 4):S227-S233.
22. Humar A, Michaels M; AST IDWorking Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262-274.
23. Pang XL, Doucette K, LeBlanc B, Cockfield SM, Preiksaitis JK. Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study. J Clin Microbiol. 2007;45(11): 3568-3573.
24. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8(1):3-15.
25. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus vs cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5(3):582-594.
26. Leung AY, Chan MT, Yuen KY, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40 (4):528-537.
27. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res. 2011;92(1):115-123.
28. Lee BT, Gabardi S, Grafals M, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J AmSoc Nephrol. 2014;9(3):583-589.
29. Rafat C, Vimont S, Ancel PY, et al. Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients. Transpl Infect Dis. 2011;13(4):344-352.
30. Zeidan S, Esposito L, Rostaing L, Kamar N. The Achilles tendon of preventing BK virus nephropathy. Transpl Infect Dis. 2013;15(6):268-269.
31. Alméras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis. 2011;13(2):101-108.
32. Ali SH, Chandraker A, DeCaprio JA. Inhibition of simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther. 2007;12(1):1-6.
33. Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500mg) vs ciprofloxacin (500mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents. 2006;28(6):551-559.